Alliance Cancer Specialists, Horsham
University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
University of Pittsburgh (UPMC), Pittsburgh

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06369285

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Penn State Milton S. Hershey Medical Center, Hershey

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06324357

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

Allegheny General Hospital, Pittsburgh

Menerima pesertaStudi observasional

Usia 20 hingga 89 · Wanita · Diperbarui 30 Sep 2026 · NCT07023887

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

AHN Allegheny General Hospital, Pittsburgh
Allegheny General Hospital, Pittsburgh

Menerima peserta

Usia 20 hingga 89 · Wanita · Diperbarui 30 Sep 2026 · NCT07698314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Pittsburgh

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT05877599

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

AHN Allegheny General Hospital, Pittsburgh
AHN Allegheny General Hospital, Pittsburgh

Menerima peserta

Usia 20 hingga 89 · Wanita · Diperbarui 28 Sep 2026 · NCT07704476

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, Philadelphia

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
Cancer Care Associates Of York ( Site 0063), York

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07060807

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

Menerima peserta

Usia 30 ke atas · Wanita · Diperbarui 25 Sep 2026 · NCT02945579

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Penn Medicine - Lancaster General Hospital, Lancaster
Capital Health Hematology Oncology Specialists, Newton
Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
dan 2 lainnya

Menerima pesertaFase 3

Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Horsham
Clinical Trial Site, Sayre

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Allegheny (AHN), Pittsburgh

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

St. Luke's University Health Network, Bethlehem
Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
University of Pennsylvania Hospital, Philadelphia
dan 3 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

University of Pittsburgh Medical Center, Pittsburgh

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

University of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

University of Pennsylvania/Abramson Cancer Center, Philadelphia

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07340541

Identifying Patterns in the Breath of Individuals With Breast Cancer

Weinstein Imaging Associates, Pittsburgh

Menerima pesertaStudi observasionalSukarelawan sehat diterima

Usia 40 hingga 74 · Wanita · Diperbarui 18 Sep 2026 · NCT06512350

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Lehigh Valley Health Network - Cedar Crest, Allen
Consultants In Medical Oncology and Hematology, P.C., Broomall
Penn State Milton S. Hershey Medical Center, Hershey
dan 5 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

Research Site, Pittsburgh

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT05123482

Active Surveillance in Older Women With ER+ Breast Cancer

University of Pittsburgh Medical Center, Pittsburgh

Menerima pesertaStudi observasional

Usia 70 ke atas · Wanita · Diperbarui 11 Sep 2026 · NCT07262138

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

St. Luke's University Health Network, Bethlehem
Guthrie Medical Group, Sayre

Menerima pesertaFase 1

Usia 18 hingga 55 · Wanita · Diperbarui 9 Sep 2026 · NCT07310420

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Penn State Health Milton S. Hershey Medical Center, Hershey
University of Pennsylvania - Abramson Cancer Center, Philadelphia
UPMC - Hillman Cancer Center, Pittsburgh

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

University of Pennsylvania, Philadelphia

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05315700

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Penn State Cancer Institute, Hershey

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT04886531

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

UPMC Hillman Cancer Center - Magee-Women?s Hospital, Pittsburgh

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06790693

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07216105

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

Abramson Cancer Center, Philadelphia

Menerima pesertaStudi observasional

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05964504

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
dan 56 lainnya

Menerima pesertaFase 3

Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

UPMC Hillman Cancer Center, Pittsburgh

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
UPMC, Pittsburgh

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963

Biennial CEM in Women With a Personal History of Breast Cancer

UPMC Magee-Womens Imaging - Bethel Park, Bethel Park
UPMC Magee at the Lemieux Sports Complex, Cranberry Township
Magee Womancare Monroeville, Monroeville
dan 3 lainnya

Menerima pesertaSukarelawan sehat diterima

Usia 30 hingga 79 · Wanita · Diperbarui 19 Agu 2026 · NCT06105749

ATEMPT 2.0: Adjuvant T-DM1 vs TH

University of Pennsylvania, Abramson Cancer Center, Philadelphia
University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital, Pittsburgh

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04893109

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Menerima peserta

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT02732171

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

AHN Allegheny General Hospital, Pittsburgh

Menerima peserta

Usia 20 hingga 89 · Wanita · Diperbarui 17 Agu 2026 · NCT07739563

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.